29 min

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease JAMA Neurology Author Interviews

    • Medicine

Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

  • American Medical Association, 2020

Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

29 min

  • American Medical Association, 2020

More by JAMA Network

JAMA Clinical Reviews
JAMA Clinical Reviews
JAMA Network
JAMA Medical News
JAMA Medical News
JAMA Network
JAMAevidence JAMA Guide to Statistics and Methods
JAMAevidence JAMA Guide to Statistics and Methods
JAMA Network
JAMA Psychiatry Author Interviews
JAMA Psychiatry Author Interviews
JAMA Network
JAMA Pediatrics Editors' Summary
JAMA Pediatrics Editors' Summary
JAMA Network
JAMA Cardiology Author Interviews
JAMA Cardiology Author Interviews
JAMA Network